Status:
COMPLETED
Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Urinary Infections
Eligibility:
All Genders
16+ years
Brief Summary
The primary objective is to study the efficacy of piperacillin/tazobactam in patients with complicated urinary tract infections
Eligibility Criteria
Inclusion
- Hospitalized patients over 16 years of age with complicated urinary infection produced by bacteria that are suspected to be susceptible to treatment with Piperacillin-tazobactam.
Exclusion
- Patients known, or thought to be hypersensitivity to beta-lactams
- Patients with an uncomplicated urinary tract infection
Key Trial Info
Start Date :
June 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2007
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT00195286
Start Date
June 1 2004
End Date
July 1 2007
Last Update
September 25 2009
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Antequera (Málaga), Spain
2
Ávila, Spain
3
Barcelona, Spain
4
Berga (Barcelona), Spain